Shanghai Henlius Biotech (HKG:2696) obtained clinical trial approval for HLX48 for injection from China's National Medical Products Administration, according to a Thursday filing with the Hong Kong bourse.
The firm developed the drug to treat advanced/metastatic solid tumors.